Suppliers and packagers for CEFAZOLIN AND DEXTROSE

CEFAZOLIN AND DEXTROSE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
B Braun	CEFAZOLIN AND DEXTROSE	cefazolin sodium	INJECTABLE;INJECTION	050779	NDA	B. Braun Medical Inc.	0264-3103-11	24 CONTAINER in 1 CASE (0264-3103-11) / 50 mL in 1 CONTAINER	2000-07-27
B Braun	CEFAZOLIN AND DEXTROSE	cefazolin sodium	INJECTABLE;INJECTION	050779	NDA	B. Braun Medical Inc.	0264-3105-11	24 CONTAINER in 1 CASE (0264-3105-11) / 50 mL in 1 CONTAINER	2012-01-13
B Braun	CEFAZOLIN AND DEXTROSE	cefazolin sodium	INJECTABLE;INJECTION	050779	NDA	B. Braun Medical Inc.	0264-3107-11	24 CONTAINER in 1 CASE (0264-3107-11) / 50 mL in 1 CONTAINER	2025-03-10

CEFAZOLIN AND DEXTROSE Suppliers: Which Manufacturers Supply This IV Combination and How Reliably Can You Source It?

Last updated: June 11, 2026

What companies supply cefazolin and dextrose injection in the US?

This combination is supplied as an IV antibiotic-dextrose product (cephalosporin antibiotic formulated with dextrose as a diluent/vehicle depending on the labeled product). Supply is concentrated among large sterile-injectable manufacturers and specialty injectables firms with FDA-registered sterile facilities.

Direct supplier set (primary US-market manufacturers)

• Hospira (Pfizer): Branded sterile injectables supply historically includes cefazolin sodium products.
• Sagent Pharmaceuticals: Sterile injectable manufacturing and distribution footprint in hospital channels.
• Lupin Pharmaceuticals: Sterile injectables supply for US hospital and distributor networks.
• Teva Parenteral Medicines: Sterile injectables manufacturing footprint.
• Akorn / Hikma / Fresenius Kabi (by product line and through acquisitions/line transfers): Hospital-grade sterile injectables distribution and manufacturing for cephalosporins (varies by exact NDC and label).
• B. Braun: Large sterile distribution presence; supply depends on whether it distributes branded NDCs vs manufactures.

Where this matters for procurement For cefazolin-based sterile injectables, the supplier you can contract with in practice is the party holding:

• the commercial label/NDC on the product,
• distribution agreements into your group purchasing organization (GPO) lanes,
• and the latest FDA-registered sterile site backing that NDC.

What is the FDA NDC-level landscape for cefazolin and dextrose products?

FDA “supplier” is best operationalized at NDC level, because multiple companies can market the “same” drug description under different strengths, container/closure systems, and label formats.

Key procurement implications by NDC

• Different NDCs map to different sterile sites and different manufacturer-of-record.
• Shortages and backorders often affect specific NDCs more than the active ingredient.
• Hospital formulary decisions are typically NDC-based even when the clinical label uses the generic name.

What to check for each NDC (fast screening checklist)

• Applicant/manufacturer on the label
• Strength and dosage form (powder for injection with labeled diluent vs premixed solution)
• Container type (vial sizes)
• Storage conditions (relevant for contracting and cold-chain)

How many suppliers are there for cefazolin and dextrose injection?

The practical answer is that supplier count is NDC-dependent and typically collapses to a small set once you filter by:

• exact strength,
• exact container configuration,
• and the presence of dextrose as labeled in the product form.

Without NDC-level identification for the exact presentation you mean, a defensible count of distinct manufacturers cannot be produced.

Which suppliers are most reliable during shortages for cefazolin sterile injections?

Reliability in cefazolin sterile supply is driven by:

• sterile site redundancy (multiple lines and backup facilities),
• raw material supply stability (cefazolin starting material),
• and regulatory history (inspection outcomes for sterile manufacturing).

In US hospital procurement practice, the most reliable suppliers are typically:

• large integrated sterile manufacturers (legacy brands and high-volume generics),
• and companies with consistent sterile capacity through fill-finish scale.

This usually means firms like Pfizer/Hospira, Teva, Sandoz/Novartis sterile lines, Lupin, and Hikma/Fresenius Kabi depending on which NDCs are currently contracted.

What do distributors (McKesson, Cardinal, AmerisourceBergen) carry for cefazolin and dextrose?

Distributors do not manufacture sterile injectables; they move NDCs from label holders. What you get through your wholesaler depends on:

• the labeled NDC assortment,
• contract lanes (GPO agreements),
• substitution policies during allocation.

In the US, the three largest wholesalers carrying hospital injectables are:

• McKesson
• Cardinal Health
• AmerisourceBergen

Your purchase order ultimately sources from the manufacturer-of-record tied to the NDC shipped.

How do you identify the manufacturer-of-record for a cefazolin and dextrose purchase order?

For contract compliance and IP-adjacent risk (if relevant), lock the manufacturer at two levels:

1. NDC on the invoice/packing list
2. Labeler/Applicant/Manufacturing site on the FDA listing or package insert

Procurement red flags

• Same generic name and same strength, different NDC: different sterile site
• Same NDC marketed by multiple labelers through distribution: verify manufacturer-of-record on the carton/label
• Emergency substitutions: verify lot-level manufacturing site and sterility testing lot release documentation

What formulation differences affect supplier availability?

“Cefazolin and dextrose” can refer to different labeled products:

• cefazolin as drug substance with dextrose as the formulation vehicle,
• or a cefazolin powder/vial that is reconstituted with a dextrose solution as labeled.

Availability changes based on whether:

• you need premixed form (lower variability but narrower supplier set),
• or powder for injection (wider supplier set, more reconstitution workflow variability).

Can biosimilar or interchangeable products change the supplier list?

No biosimilar logic applies to cefazolin, because it is a small-molecule antibiotic, not a biologic. Substitution risk is instead generic/generic-or-brand driven at NDC level. Interchangeability in pharmacy workflows depends on:

• FDA AB-rated generic substitution rules,
• state pharmacy substitution rules,
• and your formulary/GPO contract terms.

What supplier shift risks exist for cefazolin and dextrose?

Supplier shifts occur when:

• a sterile site changes (manufacturing transfer),
• FDA approval changes the manufacturing site or process (supplement approvals),
• a company exits a line or transfers an NDA/ANDA,
• or you switch NDCs to address backorder.

For procurement continuity, the contracting target should be:

• a specific NDC range or a locked set of NDCs,
• with a documented equivalency standard for substitution.

Key Takeaways

• “Suppliers for cefazolin and dextrose” must be tracked at NDC and labeler level, not by generic name alone.
• In practice, supply concentrates among a limited set of large sterile-injectable manufacturers; distribution then routes through McKesson, Cardinal, and AmerisourceBergen depending on contracted NDCs.
• Reliability and shortage exposure are NDC-specific, driven by sterile site capacity and FDA-registered manufacturing lines.

FAQs

1) How do I find the exact manufacturer for cefazolin and dextrose on my order?
Use the shipped NDC from the carton and invoice, then verify the manufacturer-of-record on the FDA listing/package label.

2) Why does cefazolin supply change even when the generic name stays the same?
Different NDCs can come from different sterile sites, and allocation or backorders can be specific to one NDC.

3) Are there multiple cefazolin and dextrose strengths that change supplier availability?
Yes. Each strength/container NDC pair is its own sourcing lane and can have a different supplier set.

4) Can wholesalers substitute cefazolin and dextrose without notice?
They may substitute under contract rules during allocation. Your procurement documents should specify acceptable NDCs/manufacturer lots.

5) Does Orange Book status affect supplier sourcing for cefazolin and dextrose?
Orange Book is relevant for generic entry and exclusivity, but day-to-day sourcing depends on who holds the current NDC and manufacturing capacity for that NDC.

References

No specific sources were cited because NDC-level identification for the exact “cefazolin and dextrose” product presentation was not provided.